Read the full stored bill text
SECOND REGULAR SESSION
SENATE BILL NO. 1724
103RD GENERAL ASSEMBLY
INTRODUCED BY SENATOR BROWN (16).
7309S.01I KRISTINA MARTIN, Secretary
AN ACT
To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to xylazine.
Be it enacted by the General Assembly of the State of Missouri, as follows:
Section A. Section 195.017, RSMo, is repealed and one new 1
section enacted in lieu thereof, to be known as section 195.017, 2
to read as follows:3
195.017. 1. The department of health and senior 1
services shall place a substance in Schedule I if it finds 2
that the substance: 3
(1) Has high potential for abuse; and 4
(2) Has no accepted medical use in treatment in the 5
United States or lacks accepted safety for use in treatment 6
under medical supervision. 7
2. Schedule I: 8
(1) The controlled substances listed in this 9
subsection are included in Schedule I; 10
(2) Any of the following opiates, including their 11
isomers, esters, ethers, salts, and salts of isomers, 12
esters, and ethers, unless specifically excepted, whenever 13
the existence of these isomers, esters, ethers and salts is 14
possible within the specific chemical designation: 15
(a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2- 16
phenethyl)-4-piperidinyl)-N-phenylacetamide); 17
(b) Acetylmethadol; 18
SB 1724 2
(c) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- 19
phenylacetamide); 20
(d) Acryl fentanyl (-(1-phenethylpiperidin-4-yl)-N- 21
phenylacrylamide); 22
(e) AH-7921(3,4-dichloro-N-[(1-dimethylamino) 23
cyclohexylmethyl] benzamide); 24
(f) Allylprodine; 25
(g) Alphacetylmethadol (except levoalphacetylmethadol, 26
also known as levo-alpha-acetylmethadol levothadyl acetate 27
or LAAM); 28
(h) Alphameprodine; 29
(i) Alphamethadol; 30
(j) Alpha-methylfentanyl (N-1-(alphamethyl-beta- 31
phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2- 32
phenylethyl)-4 ((N-propanilido) piperidine); 33
(k) Alpha-methylthiofentanyl (N-(1-methyl-2-(2- 34
thienyl) ethyl-4-piperidinyl)-N-phenylpropanamide); 35
(l) Benzethidine; 36
(m) Betacetylmethadol; 37
(n) Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)- 38
4-piperidinyl)-N-phenylpropanamide); 39
(o) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2- 40
phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide); 41
(p) Betameprodine; 42
(q) Betamethadol; 43
(r) Betaprodine; 44
(s) Clonitazene; 45
(t) Dextromoramide; 46
(u) Diampromide; 47
(v) Cyclopropyl fentanyl; 48
(w) Diethylthiambutene; 49
(x) Difenoxin; 50
SB 1724 3
(y) Dimenoxadol; 51
(z) Dimepheptanol; 52
(aa) Dimethylthiambutene; 53
(bb) Dioxaphetyl butyrate; 54
(cc) Dipipanone; 55
(dd) Ethylmethylthiambutene; 56
(ee) Etonitazene; 57
(ff) Etoxeridine; 58
(gg) 4-fluoroisobutyryl fentanyl -(4-fluorophenyl)-N- 59
(1-phenethylpiperidin-4-yl)isobutyramide; 60
(hh) Furanyl fentanyl -(1-phenethylpiperidin-4-yl)-N- 61
phenylfuran-2-carboxamide; 62
(ii) Furethidine; 63
(jj) Hydroxypethidine; 64
(kk) Ketobemidone; 65
(ll) Levomoramide; 66
(mm) Levophenacylmorphan; 67
(nn) 3-Methylfentanyl (N-(3-methyl-1-(2-phenylethyl)-4- 68
piperidyl)-N-phenylproanamide), its optical and geometric 69
isomers, salts, and salts of isomers; 70
(oo) 3-Methylthiofentanyl (N-((3-methyl-1-(2- 71
thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide); 72
(pp) Methoxyacetyl fentanyl (2-methoxy-N-(1- 73
phenethylpiperidin-4-yl)-N-phenylacetamide); 74
(qq) Morpheridine; 75
(rr) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); 76
(ss) MT-45(1-cyclohexyl-4-(1,2-diphenylethyl) 77
piperazine); 78
(tt) Noracymethadol; 79
(uu) Norlevorphanol; 80
(vv) Normethadone; 81
(ww) Norpipanone; 82
SB 1724 4
(xx) Ocfentanil N-(2-fluorophenyl)-2-methoxy-N-(1- 83
phenethylpiperidin-4-yl)acetamide; 84
(yy) Ortho-fluorofentanyl (N-2-(1-phenethylpiperidin- 85
yl)propionamide); other name 2-fluorofentanyl; 86
(zz) para-fluorobutyryl fentanyl (N-4-fluorophenyl)-N- 87
(1-phenethylpiperidin-4-yl)butyramide; 88
(aaa) Para-fluorofentanyl (N-(4-fluorophenyl)-N-(1-(2- 89
phenethyl)-4-piperidinyl) propanamide; 90
(bbb) PEPAP (1-(2-phenethyl)-4-phenyl-4- 91
acetoxypiperidine); 92
(ccc) Phenadoxone; 93
(ddd) Phenampromide; 94
(eee) Phenomorphan; 95
(fff) Phenoperidine; 96
(ggg) Piritramide; 97
(hhh) Proheptazine; 98
(iii) Properidine; 99
(jjj) Propiram; 100
(kkk) Racemoramide; 101
(lll) Tetrahydrofuranyl fentanyl (N-(1- 102
phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2- 103
carboxamide); 104
(mmm) Thiofentanyl (-phenyl-N-(1-(2-thienyl)ethyl-4- 105
piperidinyl)-propanamide; 106
(nnn) Tilidine; 107
(ooo) Trimeperidine; 108
(3) Any of the following opium derivatives, their 109
salts, isomers and salts of isomers unless specifically 110
excepted, whenever the existence of these salts, isomers and 111
salts of isomers is possible within the specific chemical 112
designation: 113
(a) Acetorphine; 114
SB 1724 5
(b) Acetyldihydrocodeine; 115
(c) Benzylmorphine; 116
(d) Codeine methylbromide; 117
(e) Codeine-N-Oxide; 118
(f) Cyprenorphine; 119
(g) Desomorphine; 120
(h) Dihydromorphine; 121
(i) Drotebanol; 122
(j) Etorphine (except hydrochloride salt); 123
(k) Heroin; 124
(l) Hydromorphinol; 125
(m) Methyldesorphine; 126
(n) Methyldihydromorphine; 127
(o) Morphine methylbromide; 128
(p) Morphine methylsulfonate; 129
(q) Morphine-N-Oxide; 130
(r) Myrophine; 131
(s) Nicocodeine; 132
(t) Nicomorphine; 133
(u) Normorphine; 134
(v) Pholcodine; 135
(w) Thebacon; 136
(4) Any of the following opiate similar synthetic 137
substances scheduled by the U.S. Drug Enforcement 138
Administration as substances that share a pharmacological 139
profile similar to fentanyl, morphine, and other synthetic 140
opioids, unless specifically excepted or unless listed in 141
another schedule: 142
(a) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- 143
phenylbutyramide); 144
(b) U-47700 (3,4-Dichloro-N-[2-(dimethylamino) 145
cyclohexyl]--methyl benzamide). 146
SB 1724 6
(5) Any material, compound, mixture or preparation 147
which contains any quantity of the following hallucinogenic 148
substances, their salts, isomers and salts of isomers, 149
unless specifically excepted, whenever the existence of 150
these salts, isomers, and salts of isomers is possible 151
within the specific chemical designation: 152
(a) Alpha-ethyltryptamine; 153
(b) 4-bromo-2,5-dimethoxyamphetamine; 154
(c) 4-bromo-2,5-dimethoxyphenethylamine; 155
(d) 2,5-dimethoxyamphetamine; 156
(e) 2,5-dimethoxy-4-ethylamphetamine; 157
(f) 2,5-dimethoxy-4-(n)-propylthiophenethylamine; 158
(g) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine; 159
(h) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine; 160
(i) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine; 161
(j) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine; 162
(k) 2-(2,5-Dimethoxyphenyl) ethanamine; 163
(l) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine; 164
(m) 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine; 165
(n) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine; 166
(o) 2-(4-Isopropylthio)-2,5-dimethoxyphenyl) 167
ethanamine; 168
(p) 4-methoxyamphetamine; 169
(q) 5-methoxy-3,4-methylenedioxyamphetamine; 170
(r) 4-methyl-2, 5-dimethoxyamphetamine; 171
(s) 3,4-methylenedioxyamphetamine; 172
(t) 3,4-methylenedioxymethamphetamine; 173
(u) 3,4-methylenedioxy-N-ethylamphetamine; 174
(v) N-hydroxy-3, 4-methylenedioxyamphetamine; 175
(w) 3,4,5-trimethoxyamphetamine; 176
(x) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine; 177
(y) Alpha-methyltryptamine; 178
SB 1724 7
(z) Bufotenine; 179
(aa) Diethyltryptamine; 180
(bb) Dimethyltryptamine; 181
(cc) 5-methoxy-N,N-diisopropyltryptamine; 182
(dd) Ibogaine; 183
(ee) Lysergic acid diethylamide; 184
(ff) Marijuana or marihuana, except industrial hemp; 185
(gg) Mescaline; 186
(hh) Parahexyl; 187
(ii) Peyote, to include all parts of the plant 188
presently classified botanically as Lophophora williamsii 189
Lemaire, whether growing or not; the seeds thereof; any 190
extract from any part of such plant; and every compound, 191
manufacture, salt, derivative, mixture or preparation of the 192
plant, its seed or extracts; 193
(jj) N-ethyl-3-piperidyl benzilate; 194
(kk) N-methyl-3-piperidyl benzilate; 195
(ll) Psilocybin; 196
(mm) Psilocyn; 197
(nn) Tetrahydrocannabinols naturally contained in a 198
plant of the genus Cannabis (cannabis plant), except 199
industrial hemp, as well as synthetic equivalents of the 200
substances contained in the cannabis plant, or in the 201
resinous extractives of such plant, or synthetic substances, 202
derivatives and their isomers, or both, with similar 203
chemical structure and pharmacological activity to those 204
substances contained in the plant, such as the following: 205
a. 1 cis or trans tetrahydrocannabinol and their 206
optical isomers; 207
b. 6 cis or trans tetrahydrocannabinol and their 208
optical isomers; 209
SB 1724 8
c. 3,4 cis or trans tetrahydrocannabinol and their 210
optical isomers; 211
d. Any compounds of these structures, regardless of 212
numerical designation of atomic positions covered; 213
(oo) Ethylamine analog of phencyclidine; 214
(pp) Pyrrolidine analog of phencyclidine; 215
(qq) Thiophene analog of phencyclidine; 216
(rr) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine; 217
(ss) Salvia divinorum; 218
(tt) Salvinorin A; 219
(uu) Synthetic cannabinoids: 220
a. Any compound structurally derived from 3-(1- 221
naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by 222
substitution at the nitrogen atom of the indole ring by 223
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 224
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4- 225
morpholinyl)ethyl group, whether or not further substituted 226
in the indole ring to any extent, whether or not substituted 227
in the naphthyl ring to any extent. Including, but not 228
limited to: 229
(i) AM2201, or 1-(5-fluoropentyl)-3-(1- 230
naphthoyl)indole; 231
(ii) JWH-007, or 1-pentyl-2-methyl-3-(1- 232
naphthoyl)indole; 233
(iii) JWH-015, or 1-propyl-2-methyl-3-(1- 234
naphthoyl)indole; 235
(iv) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole; 236
(v) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole; 237
(vi) JWH-073, or 1-butyl-3-(1-naphthoyl)indole; 238
(vii) JWH-081, or 1-pentyl-3-(4-methoxy-1- 239
naphthoyl)indole; 240
SB 1724 9
(viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1- 241
naphthoyl)indole; 242
(ix) JWH-122, or 1-pentyl-3-(4-methyl-1- 243
naphthoyl)indole; 244
(x) JWH-164, or 1-pentyl-3-(7-methoxy-1- 245
naphthoyl)indole; 246
(xi) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1- 247
naphthoyl)indole; 248
(xii) JWH-210, or 1-pentyl-3-(4-ethyl-1- 249
naphthoyl)indole; 250
(xiii) JWH-398, or 1-pentyl-3-(4-chloro-1- 251
naphthoyl)indole; 252
b. Any compound structurally derived from 3-(1- 253
naphthoyl)pyrrole by substitution at the nitrogen atom of 254
the pyrrole ring by alkyl, haloalkyl, alkenyl, 255
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- 256
piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether 257
or not further substituted in the pyrrole ring to any 258
extent, whether or not substituted in the naphthyl ring to 259
any extent; 260
c. Any compound structurally derived from 1-(1- 261
naphthylmethyl)indene by substitution at the 3-position of 262
the indene ring by alkyl, haloalkyl, alkenyl, 263
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- 264
piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether 265
or not further substituted in the indene ring to any extent, 266
whether or not substituted in the naphthyl ring to any 267
extent; 268
d. Any compound structurally derived from 3- 269
phenylacetylindole by substitution at the nitrogen atom of 270
the indole ring with alkyl, haloalkyl, alkenyl, 271
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- 272
SB 1724 10
piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether 273
or not further substituted in the indole ring to any extent, 274
whether or not substituted in the phenyl ring to any 275
extent. Including, but not limited to: 276
(i) JWH-201, or 1-pentyl-3-(4- 277
methoxyphenylacetyl)indole; 278
(ii) JWH-203, or 1-pentyl-3-(2- 279
chlorophenylacetyl)indole; 280
(iii) JWH-250, or 1-pentyl-3-(2- 281
methoxyphenylacetyl)indole; 282
(iv) JWH-251, or 1-pentyl-3-(2- 283
methylphenylacetyl)indole; 284
(v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2- 285
methoxyphenylacetyl)indole; 286
e. Any compound structurally derived from 2-(3- 287
hydroxycyclohexyl)phenol by substitution at the 5-position 288
of the phenolic ring by alkyl, haloalkyl, alkenyl, 289
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- 290
piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether 291
or not substituted in the cyclohexyl ring to any extent. 292
Including, but not limited to CP 47, 497 and homologues, or 293
2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2- 294
yl)phenol, where side chain n=5, and homologues where side 295
chain n-4,6, or 7; 296
f. Any compound containing a 3-(benzoyl)indole 297
structure with substitution at the nitrogen atom of the 298
indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 299
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4- 300
morpholinyl)ethyl group, whether or not further substituted 301
in the indole ring to any extent and whether or not 302
substituted in the phenyl ring to any extent. Including, 303
but not limited to: 304
SB 1724 11
(i) AM-694, or 1-(5-fluoropentyl)-3-(2- 305
iodobenzoyl)indole; 306
(ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR- 307
19 and RCS-4); 308
g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6- 309
methyl-3-[(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a- 310
octahydrophenanthridin-1-yl] acetate; 311
h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6- 312
dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 313
tetrahydrobenzo[c]chromen-1-ol; 314
i. HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)- 315
6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 316
tetrahydrobenzo[c]chromen-1-ol; 317
j. Dimethylheptylpyran, or DMHP; 318
(6) Any material, compound, mixture or preparation 319
containing any quantity of the following substances having a 320
depressant effect on the central nervous system, including 321
their salts, isomers and salts of isomers whenever the 322
existence of these salts, isomers and salts of isomers is 323
possible within the specific chemical designation: 324
(a) Gamma-hydroxybutyric acid; 325
(b) Mecloqualone; 326
(c) Methaqualone; 327
(7) Any material, compound, mixture or preparation 328
containing any quantity of the following substances having a 329
stimulant effect on the central nervous system, including 330
their salts, isomers and salts of isomers: 331
(a) Aminorex; 332
(b) N-benzylpiperazine; 333
(c) Cathinone; 334
(d) Fenethylline; 335
(e) 3-Fluoromethcathinone; 336
SB 1724 12
(f) 4-Fluoromethcathinone; 337
(g) Mephedrone, or 4-methylmethcathinone; 338
(h) Methcathinone; 339
(i) 4-methoxymethcathinone; 340
(j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4- 341
methyl-5-phenyl-2-oxazolamine); 342
(k) Methylenedioxypyrovalerone, MDPV, or 1-(1,3- 343
Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone; 344
(l) Methylone, or 3,4-Methylenedioxymethcathinone; 345
(m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP; 346
(n) N-ethylamphetamine; 347
(o) N,N-dimethylamphetamine; 348
(p) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB- 349
22; QUPIC); 350
(q) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- 351
carboxylate (5-fluoro-PB-22; 5F-PB-22); 352
(r) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4- 353
fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA); 354
(s) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl- 355
1H-indazole-3-carboxamide (ADB-PINACA); 356
(8) A temporary listing of substances subject to 357
emergency scheduling under federal law shall include any 358
material, compound, mixture or preparation which contains 359
any quantity of the following substances: 360
(a) (1-pentyl-1H-indol-3-yl)(2,2,3,3- 361
tetramethylcyclopropyl)methanone, its optical, positional, 362
and geometric isomers, salts, and salts of isomers; 363
(b) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- 364
tetramethylcyclopropyl)methanone, its optical, positional, 365
and geometric isomers, salts, and salts of isomers; 366
SB 1724 13
(c) N-(1-adamantyl)-1-pentyl-1H-indazole-3- 367
carboxamide, its optical, positional, and geometric isomers, 368
salts, and salts of isomers; 369
(d) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2- 370
methoxybenzyl)ethanamine, its optical, positional, and 371
geometric isomers, salts, and salts of isomers; 372
(e) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2- 373
methoxybenzyl)ethanamine, its optical, positional, and 374
geometric isomers, salts, and salts of isomers; 375
(f) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2- 376
methoxybenzyl)ethanamine, its optical, positional, and 377
geometric isomers, salts, and salts of isomers; 378
(g) 4-methyl-N-ethylcathinone, its optical, 379
positional, and geometric isomers, salts, and salts of 380
isomers; 381
(h) 4-methyl-alpha-pyrrolidinopropiophenone, its 382
optical, positional, and geometric isomers, salts, and salts 383
of isomers; 384
(i) Alpha-pyrrolidinopentiophenone, its optical, 385
positional, and geometric isomers, salts, and salts of 386
isomers; 387
(j) Butylone, its optical, positional, and geometric 388
isomers, salts, and salts of isomers; 389
(k) Pentedrone, its optical, positional, and geometric 390
isomers, salts, and salts of isomers; 391
(l) Pentylone, its optical, positional, and geometric 392
isomers, salts, and salts of isomers; 393
(m) Naphyrone, its optical, positional, and geometric 394
isomers, salts, and salts of isomers; 395
(n) Alpha-pyrrolidinobutiophenone, its optical, 396
positional, and geometric isomers, salts, and salts of 397
isomers; 398
SB 1724 14
(o) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1- 399
(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, 400
positional, and geometric isomers, salts, and salts of 401
isomers; 402
(p) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H- 403
indazole-3-carboxamide, its optical, positional, and 404
geometric isomers, salts, and salts of isomers; 405
(q) [1-(5-fluoropentyl)-1H-indazole-3-yl](naphthalen-1- 406
yl)methanone, its optical, positional, and geometric 407
isomers, salts, and salts of isomers; 408
(r) N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin- 409
4-yl]-N-phenylpropionamide, its isomers, esters, ethers, 410
salts, and salts of isomers, esters, and ethers; 411
(s) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, 412
its optical, positional, and geometric isomers, salts, and 413
salts of isomers; 414
(t) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- 415
(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, 416
positional, and geometric isomers, salts, and salts of 417
isomers; 418
(u) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 419
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 420
and geometric isomers, salts, and salts of isomers; 421
(v) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 422
carboxamido)-3-methylbutanoate, its optical, positional, and 423
geometric isomers, salts, and salts of isomers; 424
(w) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole- 425
3-carboxamide, its optical, positional, and geometric 426
isomers, salts, and salts of isomers; 427
(x) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4- 428
fluorobenzyl)-1H-indazole-3-carboxamide, its optical, 429
SB 1724 15
positional, and geometric isomers, salts, and salts of 430
isomers; 431
(y) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3- 432
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 433
and geometric isomers, salts, and salts of isomers; 434
(z) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3- 435
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 436
and geometric isomers, salts, and salts of isomers; 437
(aa) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4- 438
yl)propionamide, its isomers, esters, ethers, salts, and 439
salts of isomers, esters, and ethers; 440
(bb) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3- 441
carboxamido)-3-methylbutanoate, its optical, positional, and 442
geometric isomers, salts, and salts of isomers; 443
(cc) N-(1-phenethylpiperidin-4-yl)-N- 444
phenylcyclopropanecarboxamide, its isomers, esters, ethers, 445
salts, and salts of isomers, esters, and ethers; 446
(dd) N-(1-phenethylpiperidin-4-yl)-N- 447
phenylpentanamide, its isomers, esters, ethers, salts, and 448
salts of isomers, esters, and ethers; 449
(ee) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4- 450
yl)butyramide, its isomers, esters, ethers, salts, and salts 451
of isomers, esters, and ethers; 452
(ff) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4- 453
yl)butyramide, its isomers, esters, ethers, salts, and salts 454
of isomers, esters, and ethers; 455
(gg) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4- 456
yl)isobutyramide, its isomers, esters, ethers, salts, and 457
salts of isomers, esters, and ethers; 458
(hh) N-(1-phenethylpiperidin-4-yl)-N- 459
phenylisobutyramide, its isomers, esters, ethers, salts, and 460
salts of isomers, esters, and ethers; 461
SB 1724 16
(ii) N-(1-phenethylpiperidin-4-yl)-N- 462
phenylcyclopentanecarboxamide, its isomers, esters, ethers, 463
salts, and salts of isomers, esters, and ethers; 464
(jj) Fentanyl-related substances, their isomers, 465
esters, ethers, salts, and salts of isomers, esters, and 466
ethers. Fentanyl-related substance shall mean any substance 467
not otherwise listed under another Drug Enforcement 468
Administration Controlled Substance Code Number, and for 469
which no exemption or approval is in effect under section 470
505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 471
Section 355, that is structurally related to fentanyl by one 472
or more of the following modifications: 473
a. Replacement of the phenyl portion of the phenethyl 474
group by any monocycle, whether or not further substituted 475
in or on the monocycle; 476
b. Substitution in or on the phenethyl group with 477
alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or 478
nitro groups; 479
c. Substitution in or on the piperidine ring with 480
alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, amino or 481
nitro groups; 482
d. Replacement of the aniline ring with any aromatic 483
monocycle, whether or not further substituted in or on the 484
aromatic monocycle; or 485
e. Replacement of the N-propionyl group by another 486
acyl group; 487
(kk) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3- 488
carboxylate, its optical, positional, and geometric isomers, 489
salts, and salts of isomers (NM2201; CBL2201); 490
(ll) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5- 491
fluoropentyl)-1H-indazole-3-carboxamide, its optical, 492
SB 1724 17
positional, and geometric isomers, salts, and salts of 493
isomers (5F-AB-PINACA); 494
(mm) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H- 495
indazole-3-carboxamide, its optical, positional, and 496
geometric isomers, salts, and salts of isomers (4-CN-CUMYL- 497
BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL- 498
4CN-BINACA; SGT-78); 499
(nn) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3- 500
carboxamido)-3-methylbutanoate, its optical, positional, and 501
geometric isomers, salts, and salts of isomers (MMB-CHMICA, 502
AMB-CHMICA); 503
(oo) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H- 504
pyrrolo[2,3-b]pyridine-3-carboxamide, its optical, 505
positional, and geometric isomers, salts, and salts of 506
isomers (5F-CUMYL-P7AICA); 507
(pp) N-ethylpentylone, its optical, positional, and 508
geometric isomers, salts, and salts of isomers (ephylone, 1- 509
(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one; 510
(qq) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 511
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 512
and geometric isomers, salts, and salts of isomers (trivial 513
name: 5F-EDMB-PINACA); 514
(rr) methyl 2-(1-(5-fluoropentyl)-1H-indole-3- 515
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 516
and geometric isomers, salts, and salts of isomers (trivial 517
name: 5F-MDMB-PICA); 518
(ss) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole- 519
3-carboxamide, its optical, positional, and geometric 520
isomers, salts, and salts of isomers (trivial names: FUB- 521
AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL)); 522
(tt) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H- 523
indazole-3-carboxamide, its optical, positional, and 524
SB 1724 18
geometric isomers, salts, and salts of isomers (trivial 525
names: 5F-CUMYL-PINACA; SGT-25); 526
(uu) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3- 527
tetramethylcyclopropyl) methanone, its optical, positional, 528
and geometric isomers, salts, and salts of isomers (trivial 529
name: FUB-144); 530
(vv) N-ethylhexedrone, its optical, positional, and 531
geometric isomers, salts, and salts of isomers (Other name: 532
2-(ethylamino)-1-phenylhexan-1-one); 533
(ww) alpha-pyrrolidinohexanophenone, its optical, 534
positional, and geometric isomers, salts, and salts of 535
isomers (Other names: α-PHP; alpha-pyrrolidinohexiophenone; 536
1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one); 537
(xx) 4-methyl-alpha-ethylaminopentiophenone, its 538
optical, positional, and geometric isomers, salts, and salts 539
of isomers; (Other names: 4-MEAP; 2-(ethylamino)-1-(4- 540
methylphenyl)pentan-1-one); 541
(yy) 4'-methyl-alpha-pyrrolidinohexiophenone, its 542
optical, positional, and geometric isomers, salts, and salts 543
of isomers (Other names: MPHP; 4'-methyl-alpha- 544
pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1- 545
yl)hexan-1-one); 546
(zz) alpha-pyrrolidinoheptaphenone, its optical, 547
positional, and geometric isomers, salts, and salts of 548
isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1- 549
yl)heptan-1-one); 550
(aaa) 4'-chloro-alpha-pyrrolidinovalerophenone, its 551
optical, positional, and geometric isomers, salts, and salts 552
of isomers (Other names: 4-chloro-α-PVP; 4'-chloro-alpha- 553
pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1- 554
yl)pentan-1-one); 555
SB 1724 19
(9) Khat, to include all parts of the plant presently 556
classified botanically as catha edulis, whether growing or 557
not; the seeds thereof; any extract from any part of such 558
plant; and every compound, manufacture, salt, derivative, 559
mixture, or preparation of the plant, its seed or extracts. 560
3. The department of health and senior services shall 561
place a substance in Schedule II if it finds that: 562
(1) The substance has high potential for abuse; 563
(2) The substance has currently accepted medical use 564
in treatment in the United States, or currently accepted 565
medical use with severe restrictions; and 566
(3) The abuse of the substance may lead to severe 567
psychic or physical dependence. 568
4. The controlled substances listed in this subsection 569
are included in Schedule II: 570
(1) Any of the following substances whether produced 571
directly or indirectly by extraction from substances of 572
vegetable origin, or independently by means of chemical 573
synthesis, or by combination of extraction and chemical 574
synthesis: 575
(a) Opium and opiate; and any salt, compound, 576
derivative or preparation of opium or opiate, excluding 577
apomorphine, thebaine-derived butorphanol, dextrorphan, 578
nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone, 579
and their respective salts, but including the following: 580
a. Raw opium; 581
b. Opium extracts; 582
c. Opium fluid; 583
d. Powdered opium; 584
e. Granulated opium; 585
f. Tincture of opium; 586
g. Codeine; 587
SB 1724 20
h. Dihydroetorphine; 588
i. Ethylmorphine; 589
j. Etorphine hydrochloride; 590
k. Hydrocodone; 591
l. Hydromorphone; 592
m. Metopon; 593
n. Morphine; 594
o. Oripavine; 595
p. Oxycodone; 596
q. Oxymorphone; 597
r. Thebaine; 598
(b) Any salt, compound, derivative, or preparation 599
thereof which is chemically equivalent or identical with any 600
of the substances referred to in this subdivision, but not 601
including the isoquinoline alkaloids of opium; 602
(c) Opium poppy and poppy straw; 603
(d) Coca leaves and any salt, compound, derivative, or 604
preparation of coca leaves, and any salt, compound, 605
derivative, or preparation thereof which is chemically 606
equivalent or identical with any of these substances, but 607
not including the following: 608
a. Decocainized coca leaves or extractions of coca 609
leaves, which extractions do not contain cocaine or 610
ecgonine; or 611
b. Ioflupane; 612
(e) Concentrate of poppy straw (the crude extract of 613
poppy straw in either liquid, solid or powder form which 614
contains the phenanthrene alkaloids of the opium poppy); 615
(2) Any of the following opiates, including their 616
isomers, esters, ethers, salts, and salts of isomers, 617
whenever the existence of these isomers, esters, ethers, and 618
SB 1724 21
salts is possible within the specific chemical designation, 619
dextrorphan and levopropoxyphene excepted: 620
(a) Alfentanil; 621
(b) Alphaprodine; 622
(c) Anileridine; 623
(d) Bezitramide; 624
(e) Bulk dextropropoxyphene; 625
(f) Carfentanil; 626
(g) Dihydrocodeine; 627
(h) Diphenoxylate; 628
(i) Fentanyl; 629
(j) Isomethadone; 630
(k) Levo-alphacetylmethadol; 631
(l) Levomethorphan; 632
(m) Levorphanol; 633
(n) Metazocine; 634
(o) Methadone; 635
(p) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 636
4-diphenylbutane; 637
(q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1- 638
diphenylpropane-carboxylic acid; 639
(r) Pethidine (meperidine); 640
(s) Pethidine-Intermediate-A, 4-cyano-1-methyl-4- 641
phenylpiperidine; 642
(t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine- 643
4-carboxylate; 644
(u) Pethidine-Intermediate-C, 1-methyl-4- 645
phenylpiperdine-4-carboxylic acid; 646
(v) Phenazocine; 647
(w) Piminodine; 648
(x) Racemethorphan; 649
(y) Racemorphan; 650
SB 1724 22
(z) Remifentanil; 651
(aa) Sufentanil; 652
(bb) Tapentadol; 653
(cc) Thiafentanil; 654
(3) Any material, compound, mixture, or preparation 655
which contains any quantity of the following substances 656
having a stimulant effect on the central nervous system: 657
(a) Amphetamine, its salts, optical isomers, and salts 658
of its optical isomers; 659
(b) Lisdexamfetamine, its salts, isomers, and salts of 660
its isomers; 661
(c) Methamphetamine, its salts, isomers, and salts of 662
its isomers; 663
(d) Phenmetrazine and its salts; 664
(e) Methylphenidate; 665
(4) Any material, compound, mixture, or preparation 666
which contains any quantity of the following substances 667
having a depressant effect on the central nervous system, 668
including its salts, isomers, and salts of isomers whenever 669
the existence of those salts, isomers, and salts of isomers 670
is possible within the specific chemical designation: 671
(a) Amobarbital; 672
(b) Glutethimide; 673
(c) Pentobarbital; 674
(d) Phencyclidine; 675
(e) Secobarbital; 676
(5) Hallucinogenic substances: 677
(a) Any material or compound which contains any 678
quantity of nabilone; 679
(b) Dronabinol [(-)-Δ-9-trans tetrahydrocannabinol] in 680
an oral solution in a drug product approved for marketing by 681
the U.S. Food and Drug Administration; 682
SB 1724 23
(6) Any material, compound, mixture, or preparation 683
which contains any quantity of the following substances: 684
(a) Immediate precursor to amphetamine and 685
methamphetamine: Phenylacetone; 686
(b) Immediate precursors to phencyclidine (PCP): 687
a. 1-phenylcyclohexylamine; 688
b. 1-piperidinocyclohexanecarbonitrile (PCC); 689
(c) Immediate precursor to fentanyl: 4-anilino-N- 690
phenethyl-4-piperidine (ANPP); 691
(7) Any material, compound, mixture, or preparation 692
which contains any quantity of the following alkyl nitrites: 693
(a) Amyl nitrite; 694
(b) Butyl nitrite. 695
5. The department of health and senior services shall 696
place a substance in Schedule III if it finds that: 697
(1) The substance has a potential for abuse less than 698
the substances listed in Schedules I and II; 699
(2) The substance has currently accepted medical use 700
in treatment in the United States; and 701
(3) Abuse of the substance may lead to moderate or low 702
physical dependence or high psychological dependence. 703
6. The controlled substances listed in this subsection 704
are included in Schedule III: 705
(1) Any material, compound, mixture, or preparation 706
which contains any quantity of the following substances 707
having a potential for abuse associated with a stimulant 708
effect on the central nervous system: 709
(a) Benzphetamine; 710
(b) Chlorphentermine; 711
(c) Clortermine; 712
(d) Phendimetrazine; 713
SB 1724 24
(2) Any material, compound, mixture or preparation 714
which contains any quantity or salt of the following 715
substances or salts having a depressant effect on the 716
central nervous system: 717
(a) Any material, compound, mixture or preparation 718
which contains any quantity or salt of the following 719
substances combined with one or more active medicinal 720
ingredients: 721
a. Amobarbital; 722
b. Secobarbital; 723
c. Pentobarbital; 724
(b) Any suppository dosage form containing any 725
quantity or salt of the following: 726
a. Amobarbital; 727
b. Secobarbital; 728
c. Pentobarbital; 729
(c) Any substance which contains any quantity of a 730
derivative of barbituric acid or its salt; 731
(d) Chlorhexadol; 732
(e) Embutramide; 733
(f) Gamma hydroxybutyric acid and its salts, isomers, 734
and salts of isomers contained in a drug product for which 735
an application has been approved under Section 505 of the 736
federal Food, Drug, and Cosmetic Act; 737
(g) Ketamine, its salts, isomers, and salts of isomers; 738
(h) Lysergic acid; 739
(i) Lysergic acid amide; 740
(j) Methyprylon; 741
(k) Perampanel, and its salts, isomers, and salts of 742
isomers; 743
(l) Sulfondiethylmethane; 744
(m) Sulfonethylmethane; 745
SB 1724 25
(n) Sulfonmethane; 746
(o) Tiletamine and zolazepam or any salt thereof; 747
(3) Nalorphine; 748
(4) Any material, compound, mixture, or preparation 749
containing limited quantities of any of the following 750
narcotic drugs or their salts: 751
(a) Not more than 1.8 grams of codeine per one hundred 752
milliliters or not more than ninety milligrams per dosage 753
unit, with an equal or greater quantity of an isoquinoline 754
alkaloid of opium; 755
(b) Not more than 1.8 grams of codeine per one hundred 756
milliliters or not more than ninety milligrams per dosage 757
unit with one or more active, nonnarcotic ingredients in 758
recognized therapeutic amounts; 759
(c) Not more than 1.8 grams of dihydrocodeine per one 760
hundred milliliters or not more than ninety milligrams per 761
dosage unit, with one or more active, nonnarcotic 762
ingredients in recognized therapeutic amounts; 763
(d) Not more than three hundred milligrams of 764
ethylmorphine per one hundred milliliters or not more than 765
fifteen milligrams per dosage unit, with one or more active, 766
nonnarcotic ingredients in recognized therapeutic amounts; 767
(e) Not more than five hundred milligrams of opium per 768
one hundred milliliters or per one hundred grams or not more 769
than twenty-five milligrams per dosage unit, with one or 770
more active nonnarcotic ingredients in recognized 771
therapeutic amounts; 772
(f) Not more than fifty milligrams of morphine per one 773
hundred milliliters or per one hundred grams, with one or 774
more active, nonnarcotic ingredients in recognized 775
therapeutic amounts; 776
SB 1724 26
(5) Any material, compound, mixture, or preparation 777
containing any of the following narcotic drugs or their 778
salts: Buprenorphine; 779
(6) Anabolic steroids. Any drug or hormonal 780
substance, chemically and pharmacologically related to 781
testosterone (other than estrogens, progestins, 782
corticosteroids, and dehydroepiandrosterone) that promotes 783
muscle growth, except an anabolic steroid which is expressly 784
intended for administration through implants to cattle or 785
other nonhuman species and which has been approved by the 786
Secretary of Health and Human Services for that 787
administration. If any person prescribes, dispenses, or 788
distributes such steroid for human use, such person shall be 789
considered to have prescribed, dispensed, or distributed an 790
anabolic steroid within the meaning of this subdivision. 791
Unless specifically excepted or unless listed in another 792
schedule, any material, compound, mixture or preparation 793
containing any quantity of the following substances, 794
including its salts, esters and ethers: 795
(a) 3ß,17ß-dihydroxy-5α-androstane; 796
(b) 3α,17β-dihydroxy-5α-androstane; 797
(c) 5α-androstan-3,17-dione; 798
(d) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1- 799
ene); 800
(e) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1- 801
ene); 802
(f) 4-androstenediol (3β,17β-dihydroxy-androst-4-ene); 803
(g) 5-androstenediol (3β,17β-dihydroxy-androst-5-ene); 804
(h) 1-androstenedione ([5α]-androst-1-en-3,17-dione); 805
(i) 4-androstenedione (androst-4-en-3,17-dione); 806
(j) 5-androstenedione (androst-5-en-3,17-dione); 807
SB 1724 27
(k) Bolasterone (7α, 17α-dimethyl-17β-hydroxyandrost-4- 808
en-3-one); 809
(l) Boldenone (17β-hydroxyandrost-1,4,-diene-3-one); 810
(m) Boldione; 811
(n) Calusterone (7β, 17α-dimethyl-17β-hydroxyandrost-4- 812
en-3-one); 813
(o) Clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one); 814
(p) Dehydrochloromethyltestosterone (4-chloro-17β- 815
hydroxy-17α-methyl-androst-1,4-dien-3-one); 816
(q) Desoxymethyltestosterone; 817
(r) 4-dihydrotestosterone (17ß-hydroxy-androstan-3- 818
one); 819
(s) Drostanolone (17ß-hydroxy-2α-methyl-5α-androstan-3- 820
one); 821
(t) Ethylestrenol (17α-ethyl-17ß-hydroxyestr-4-ene); 822
(u) Fluoxymesterone (9-fluoro-17α-methyl-11ß,17ß- 823
dihydroxyandrost-4-en-3-one); 824
(v) Formebolone (2-formyl-17α-methyl-11α,17ß- 825
dihydroxyandrost-1,4-dien-3-one); 826
(w) Furazabol (17α-methyl-17ß-hydroxyandrostano[2,3-c]- 827
furazan); 828
(x) 13ß-ethyl-17ß-hydroxygon-4-en-3-one; 829
(y) 4-hydroxytestosterone (4,17ß-dihydroxy-androst-4- 830
en-3-one); 831
(z) 4-hydroxy-19-nortestosterone (4,17ß-dihydroxy-estr- 832
4-en-3-one); 833
(aa) Mestanolone (17α-methyl-17ß-hydroxy-5α-androstan- 834
3-one); 835
(bb) Mesterolone (1α- methyl-17ß-hydroxy-[5α]- 836
androstan-3-one); 837
(cc) Methandienone (17α-methyl-17ß-hydroxyandrost-1,4- 838
dien-3-one); 839
SB 1724 28
(dd) Methandriol (17α-methyl-3ß,17ß-dihydroxyandrost-5- 840
ene); 841
(ee) Methasterone (2α,17α-dimethyl-5α-androstan-17β-ol- 842
3-one); 843
(ff) Methenolone (1-methyl-17ß-hydroxy-5α-androst-1-en- 844
3-one); 845
(gg) 17α-methyl-3β,17β-dihydroxy-5α-androstane; 846
(hh) 17α-methyl-3α,17β-dihydroxy-5α-androstane; 847
(ii) 17α-methyl-3β,17β-dihydroxyandrost-4-ene; 848
(jj) 17α-methyl-4-hydroxynandrolone (17α-methyl-4- 849
hydroxy-17β-hydroxyestr-4-en-3-one); 850
(kk) Methyldienolone (17α-methyl-17β-hydroxyestra- 851
4,9(10)-dien-3-one); 852
(ll) Methyltrienolone (17α-methyl-17β-hydroxyestra- 853
4,9,11-trien-3-one); 854
(mm) Methyltestosterone (17α-methyl-17β-hydroxyandrost- 855
4-en-3-one); 856
(nn) Mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en- 857
3-one); 858
(oo) 17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy- 859
17α-methyl-5α-androst-1-en-3-one) (a.k.a. '17-α-methyl-1- 860
testosterone'); 861
(pp) Nandrolone (17β-hydroxyestr-4-ene-3-one); 862
(qq) 19-nor-4-androstenediol (3β,17β-dihydroxyestr-4- 863
ene); 864
(rr) 19-nor-4-androstenediol (3α,17β-dihydroxyestr-4- 865
ene); 866
(ss) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)- 867
diene-3,17-dione); 868
(tt) 19-nor-5-androstenediol (3β,17β-dihydroxyestr-5- 869
ene); 870
SB 1724 29
(uu) 19-nor-5-androstenediol (3α,17β-dihydroxyestr-5- 871
ene); 872
(vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione); 873
(ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione); 874
(xx) Norbolethone (13β,17α-diethyl-17β-hydroxygon-4-en- 875
3-one); 876
(yy) Norclostebol (4-chloro-17β-hydroxyestr-4-en-3- 877
one); 878
(zz) Norethandrolone (17α-ethyl-17β-hydroxyestr-4-en-3- 879
one); 880
(aaa) Normethandrolone (17α-methyl-17β-hydroxyestr-4- 881
en-3-one); 882
(bbb) Oxandrolone (17α-methyl-17β-hydroxy-2-oxa-[5α]- 883
androstan-3-one); 884
(ccc) Oxymesterone (17α-methyl-4,17β-dihydroxyandrost- 885
4-en-3-one); 886
(ddd) metholone (17α-methyl-2-hydroxymethylene-17β- 887
hydroxy-[5α]-androstan-3-one); 888
(eee) Prostanozol (17β-hydroxy-5α-androstano[3,2- 889
c]pyrazole); 890
(fff) Stanolone (Δ1-dihydrotestosterone (a.k.a. 1- 891
testosterone)(17β-hydroxy-5α-androst-1-en-3-one)); 892
(ggg) Stanozolol (17α-methyl-17ß-hydroxy-[5α]-androst- 893
2-eno[3,2-c]-pyrazole); 894
(hhh) Stenbolone (17ß-hydroxy-2-methyl-[5α]-androst-1- 895
en-3-one); 896
(iii) Testolactone (13-hydroxy-3-oxo-13,17- 897
secoandrosta-1,4-dien-17-oic acid lactone); 898
(jjj) Testosterone (17ß-hydroxyandrost-4-en-3-one); 899
(kkk) Tetrahydrogestrinone (13ß,17α-diethyl-17ß- 900
hydroxygon-4,9,11-trien-3-one); 901
(lll) Trenbolone (17ß-hydroxyestr-4,9,11-trien-3-one); 902
SB 1724 30
(mmm) Any salt, ester, or ether of a drug or substance 903
described or listed in this subdivision, except an anabolic 904
steroid which is expressly intended for administration 905
through implants to cattle or other nonhuman species and 906
which has been approved by the Secretary of Health and Human 907
Services for that administration; 908
(7) Dronabinol (synthetic) in sesame oil and 909
encapsulated in a soft gelatin capsule in a United States 910
Food and Drug Administration approved drug product; 911
(8) Any material, compound, mixture, or preparation 912
that contains xylazine, except in the following cases: 913
(a) Dispensing, prescribing, or administering to an 914
animal a drug containing xylazine that has been approved by 915
the United States Secretary of Health and Human Services 916
under 21 U.S.C. Section 360b; 917
(b) Dispensing, prescribing, or administering xylazine 918
to an animal that is permissible under 21 U.S.C. Section 919
360b(a)(4); 920
(c) Manufacturing, distributing, or using xylazine as 921
an active pharmaceutical ingredient for manufacturing an 922
animal drug: 923
a. Approved under 21 U.S.C. Section 360b; or 924
b. Issued an investigation use exemption under 21 925
U.S.C. Section 360b(j); 926
(d) Manufacturing, distributing, or using a xylazine 927
bulk chemical for pharmaceutical compounding by a licensed 928
pharmacist or veterinarian; or 929
(e) Any other use approved or permissible under 21 930
U.S.C. Section 301, et seq.; 931
(9) The department of health and senior services may 932
except by rule any compound, mixture, or preparation 933
containing any stimulant or depressant substance listed in 934
SB 1724 31
subdivisions (1) and (2) of this subsection from the 935
application of all or any part of sections 195.010 to 936
195.320 if the compound, mixture, or preparation contains 937
one or more active medicinal ingredients not having a 938
stimulant or depressant effect on the central nervous 939
system, and if the admixtures are included therein in 940
combinations, quantity, proportion, or concentration that 941
vitiate the potential for abuse of the substances which have 942
a stimulant or depressant effect on the central nervous 943
system. 944
7. The department of health and senior services shall 945
place a substance in Schedule IV if it finds that: 946
(1) The substance has a low potential for abuse 947
relative to substances in Schedule III; 948
(2) The substance has currently accepted medical use 949
in treatment in the United States; and 950
(3) Abuse of the substance may lead to limited 951
physical dependence or psychological dependence relative to 952
the substances in Schedule III. 953
8. The controlled substances listed in this subsection 954
are included in Schedule IV: 955
(1) Any material, compound, mixture, or preparation 956
containing any of the following narcotic drugs or their 957
salts calculated as the free anhydrous base or alkaloid, in 958
limited quantities as set forth below: 959
(a) Not more than one milligram of difenoxin and not 960
less than twenty-five micrograms of atropine sulfate per 961
dosage unit; 962
(b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2- 963
diphenyl-3-methyl-2-propionoxybutane); 964
SB 1724 32
(c) 2-[(dimethylamino)methyl]-1-(3- 965
methoxyphenyl)cyclohexanol, its salts, optical and geometric 966
isomers, and salts of these isomers (including tramadol); 967
(d) Any of the following limited quantities of 968
narcotic drugs or their salts, which shall include one or 969
more nonnarcotic active medicinal ingredients in sufficient 970
proportion to confer upon the compound, mixture or 971
preparation valuable medicinal qualities other than those 972
possessed by the narcotic drug alone: 973
a. Not more than two hundred milligrams of codeine per 974
one hundred milliliters or per one hundred grams; 975
b. Not more than one hundred milligrams of 976
dihydrocodeine per one hundred milliliters or per one 977
hundred grams; 978
c. Not more than one hundred milligrams of 979
ethylmorphine per one hundred milliliters or per one hundred 980
grams; 981
(2) Any material, compound, mixture or preparation 982
containing any quantity of the following substances, 983
including their salts, isomers, and salts of isomers 984
whenever the existence of those salts, isomers, and salts of 985
isomers is possible within the specific chemical designation: 986
(a) Alfaxalone; 987
(b) Alprazolam; 988
(c) Barbital; 989
(d) Bromazepam; 990
(e) Camazepam; 991
(f) Carisoprodol; 992
(g) Chloral betaine; 993
(h) Chloral hydrate; 994
(i) Chlordiazepoxide; 995
(j) Clobazam; 996
SB 1724 33
(k) Clonazepam; 997
(l) Clorazepate; 998
(m) Clotiazepam; 999
(n) Cloxazolam; 1000
(o) Delorazepam; 1001
(p) Diazepam; 1002
(q) Dichloralphenazone; 1003
(r) Estazolam; 1004
(s) Ethchlorvynol; 1005
(t) Ethinamate; 1006
(u) Ethyl loflazepate; 1007
(v) Fludiazepam; 1008
(w) Flunitrazepam; 1009
(x) Flurazepam; 1010
(y) Fospropofol; 1011
(z) Halazepam; 1012
(aa) Haloxazolam; 1013
(bb) Ketazolam; 1014
(cc) Loprazolam; 1015
(dd) Lorazepam; 1016
(ee) Lormetazepam; 1017
(ff) Mebutamate; 1018
(gg) Medazepam; 1019
(hh) Meprobamate; 1020
(ii) Methohexital; 1021
(jj) Methylphenobarbital (mephobarbital); 1022
(kk) Midazolam; 1023
(ll) Nimetazepam; 1024
(mm) Nitrazepam; 1025
(nn) Nordiazepam; 1026
(oo) Oxazepam; 1027
(pp) Oxazolam; 1028
SB 1724 34
(qq) Paraldehyde; 1029
(rr) Petrichloral; 1030
(ss) Phenobarbital; 1031
(tt) Pinazepam; 1032
(uu) Prazepam; 1033
(vv) Quazepam; 1034
(ww) Suvorexant; 1035
(xx) Temazepam; 1036
(yy) Tetrazepam; 1037
(zz) Triazolam; 1038
(aaa) Zaleplon; 1039
(bbb) Zolpidem; 1040
(ccc) Zopiclone; 1041
(3) Any material, compound, mixture, or preparation 1042
which contains any quantity of the following substance 1043
including its salts, isomers and salts of isomers whenever 1044
the existence of such salts, isomers and salts of isomers is 1045
possible: fenfluramine; 1046
(4) Any material, compound, mixture, or preparation 1047
which contains any quantity of the following substances, 1048
including its salts, isomers, and salts of isomers, whenever 1049
the existence of such salts, isomers, and salts of isomers 1050
is possible: Lorcaserin; 1051
(5) Any material, compound, mixture or preparation 1052
containing any quantity of the following substances having a 1053
stimulant effect on the central nervous system, including 1054
their salts, isomers and salts of isomers: 1055
(a) Cathine ((+)-norpseudoephedrine); 1056
(b) Diethylpropion; 1057
(c) Fencamfamin; 1058
(d) Fenproporex; 1059
(e) Mazindol; 1060
SB 1724 35
(f) Mefenorex; 1061
(g) Modafinil; 1062
(h) Pemoline, including organometallic complexes and 1063
chelates thereof; 1064
(i) Phentermine; 1065
(j) Pipradrol; 1066
(k) Sibutramine; 1067
(l) SPA ((-)-1-dimethyamino-1,2-diphenylethane); 1068
(6) Any material, compound, mixture or preparation 1069
containing any quantity of the following substance, 1070
including its salts: 1071
(a) Butorphanol (including its optical isomers); 1072
(b) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)- 1073
2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1 H- 1074
imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) 1075
(including its optical isomers) and its salts, isomers, and 1076
salts of isomers; 1077
(c) Pentazocine; 1078
(7) Ephedrine, its salts, optical isomers and salts of 1079
optical isomers, when the substance is the only active 1080
medicinal ingredient; 1081
(8) The department of health and senior services may 1082
except by rule any compound, mixture, or preparation 1083
containing any depressant substance listed in subdivision 1084
(1) of this subsection from the application of all or any 1085
part of sections 195.010 to 195.320 and sections 579.015 to 1086
579.086 if the compound, mixture, or preparation contains 1087
one or more active medicinal ingredients not having a 1088
depressant effect on the central nervous system, and if the 1089
admixtures are included therein in combinations, quantity, 1090
proportion, or concentration that vitiate the potential for 1091
SB 1724 36
abuse of the substances which have a depressant effect on 1092
the central nervous system. 1093
9. The department of health and senior services shall 1094
place a substance in Schedule V if it finds that: 1095
(1) The substance has low potential for abuse relative 1096
to the controlled substances listed in Schedule IV; 1097
(2) The substance has currently accepted medical use 1098
in treatment in the United States; and 1099
(3) The substance has limited physical dependence or 1100
psychological dependence liability relative to the 1101
controlled substances listed in Schedule IV. 1102
10. The controlled substances listed in this 1103
subsection are included in Schedule V: 1104
(1) Any compound, mixture or preparation containing 1105
any of the following narcotic drugs or their salts 1106
calculated as the free anhydrous base or alkaloid, in 1107
limited quantities as set forth below, which also contains 1108
one or more nonnarcotic active medicinal ingredients in 1109
sufficient proportion to confer upon the compound, mixture 1110
or preparation valuable medicinal qualities other than those 1111
possessed by the narcotic drug alone: 1112
(a) Not more than two and five-tenths milligrams of 1113
diphenoxylate and not less than twenty-five micrograms of 1114
atropine sulfate per dosage unit; 1115
(b) Not more than one hundred milligrams of opium per 1116
one hundred milliliters or per one hundred grams; 1117
(c) Not more than five-tenths milligram of difenoxin 1118
and not less than twenty-five micrograms of atropine sulfate 1119
per dosage unit; 1120
(2) Any material, compound, mixture or preparation 1121
which contains any quantity of the following substance 1122
having a stimulant effect on the central nervous system 1123
SB 1724 37
including its salts, isomers and salts of isomers: 1124
pyrovalerone; 1125
(3) Any compound, mixture, or preparation containing 1126
any detectable quantity of pseudoephedrine or its salts or 1127
optical isomers, or salts of optical isomers or any 1128
compound, mixture, or preparation containing any detectable 1129
quantity of ephedrine or its salts or optical isomers, or 1130
salts of optical isomers; 1131
(4) Unless specifically exempted or excluded or unless 1132
listed in another schedule, any material, compound, mixture, 1133
or preparation which contains any quantity of the following 1134
substances having a depressant effect on the central nervous 1135
system, including its salts: 1136
(a) Brivaracetam ((25)-2-[(4R)-2-oxo-4- 1137
propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; 1138
UCB-34714; Briviact); 1139
(b) Ezogabine [N-[2-amino-4(4-fluorobenzylamino)- 1140
phenyl]-carbamic acid ethyl ester]; 1141
(c) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy- 1142
propionamide]; 1143
(d) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic 1144
acid]; 1145
(5) Any drug product in finished dosage formulation 1146
that has been approved by the U.S. Food and Drug 1147
Administration that contains cannabidiol (2-[1R-3-methyl-6R- 1148
(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3- 1149
benzenediol) derived from cannabis and no more than 0.1 1150
percent (w/w) residual tetrahydro cannabinols. 1151
11. If any compound, mixture, or preparation as 1152
specified in subdivision (3) of subsection 10 of this 1153
section is dispensed, sold, or distributed in a pharmacy 1154
without a prescription: 1155
SB 1724 38
(1) All packages of any compound, mixture, or 1156
preparation containing any detectable quantity of 1157
pseudoephedrine, its salts or optical isomers, or salts of 1158
optical isomers or ephedrine, its salts or optical isomers, 1159
or salts of optical isomers, shall be offered for sale only 1160
from behind a pharmacy counter where the public is not 1161
permitted, and only by a registered pharmacist or registered 1162
pharmacy technician; and 1163
(2) Any person purchasing, receiving or otherwise 1164
acquiring any compound, mixture, or preparation containing 1165
any detectable quantity of pseudoephedrine, its salts or 1166
optical isomers, or salts of optical isomers or ephedrine, 1167
its salts or optical isomers, or salts of optical isomers 1168
shall be at least eighteen years of age; and 1169
(3) The pharmacist, intern pharmacist, or registered 1170
pharmacy technician shall require any person, prior to such 1171
person's purchasing, receiving or otherwise acquiring such 1172
compound, mixture, or preparation to furnish suitable photo 1173
identification that is issued by a state or the federal 1174
government or a document that, with respect to 1175
identification, is considered acceptable and showing the 1176
date of birth of the person; 1177
(4) The seller shall deliver the product directly into 1178
the custody of the purchaser. 1179
12. Pharmacists, intern pharmacists, and registered 1180
pharmacy technicians shall implement and maintain an 1181
electronic log of each transaction. Such log shall include 1182
the following information: 1183
(1) The name, address, and signature of the purchaser; 1184
(2) The amount of the compound, mixture, or 1185
preparation purchased; 1186
(3) The date and time of each purchase; and 1187
SB 1724 39
(4) The name or initials of the pharmacist, intern 1188
pharmacist, or registered pharmacy technician who dispensed 1189
the compound, mixture, or preparation to the purchaser. 1190
13. Each pharmacy shall submit information regarding 1191
sales of any compound, mixture, or preparation as specified 1192
in subdivision (3) of subsection 10 of this section in 1193
accordance with transmission methods and frequency 1194
established by the department by regulation; 1195
14. No person shall dispense, sell, purchase, receive, 1196
or otherwise acquire quantities greater than those specified 1197
in this chapter. 1198
15. All persons who dispense or offer for sale 1199
pseudoephedrine and ephedrine products in a pharmacy shall 1200
ensure that all such products are located only behind a 1201
pharmacy counter where the public is not permitted. 1202
16. The penalties for a knowing or reckless violation 1203
of the provisions of subsections 11 to 15 of this section 1204
are found in section 579.060. 1205
17. The scheduling of substances specified in 1206
subdivision (3) of subsection 10 of this section and 1207
subsections 11, 12, 14, and 15 of this section shall not 1208
apply to any compounds, mixtures, or preparations that are 1209
in liquid or liquid-filled gel capsule form or to any 1210
compound, mixture, or preparation specified in subdivision 1211
(3) of subsection 10 of this section which must be 1212
dispensed, sold, or distributed in a pharmacy pursuant to a 1213
prescription. 1214
18. The manufacturer of a drug product or another 1215
interested party may apply with the department of health and 1216
senior services for an exemption from this section. The 1217
department of health and senior services may grant an 1218
exemption by rule from this section if the department finds 1219
SB 1724 40
the drug product is not used in the illegal manufacture of 1220
methamphetamine or other controlled or dangerous 1221
substances. The department of health and senior services 1222
shall rely on reports from law enforcement and law 1223
enforcement evidentiary laboratories in determining if the 1224
proposed product can be used to manufacture illicit 1225
controlled substances. 1226
19. The department of health and senior services shall 1227
revise and republish the schedules annually. 1228
20. The department of health and senior services shall 1229
promulgate rules under chapter 536 regarding the security 1230
and storage of Schedule V controlled substances, as 1231
described in subdivision (3) of subsection 10 of this 1232
section, for distributors as registered by the department of 1233
health and senior services. 1234
21. Logs of transactions required to be kept and 1235
maintained by this section and section 195.417 shall create 1236
a rebuttable presumption that the person whose name appears 1237
in the logs is the person whose transactions are recorded in 1238
the logs. 1239
✓